Molecular mechanisms of oestrogen action on growth of human breast cancer cells in culture

Hormone Molecular Biology and Clinical Investigation

Volumn 9, Issue 1, 2012, Pages 65-85

  Darbre, Philippa D ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

antioestrogen; breast cancer cell growth; environmental oestrogens; oestrogen

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; CELL CYCLE PROTEIN; ENVIRONMENTAL CHEMICAL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GROWTH FACTOR;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL CULTURE; CELL CYCLE REGULATION; CELL GROWTH; CELL MOTILITY; ESTROGEN ACTIVITY; GENE EXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84875064090     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2011-0003     Document Type: Article

References (274)

1. Lippman ME, Dickson RB. Regulatory mechanisms in breast cancer. Boston: Kluwer Academic, 1990.
2. Miller WR. Estrogen and breast cancer. London: Chapman and Hall, 1996.
3. Pasqualini JR, Katzenellenbogen BS, editors. Hormone-dependent cancer. New York: Marcel Dekker, 1996.
4. Pasqualini JR, editor. Breast cancer prognosis, treatment and prevention. 2 nd ed. London, UK: Informa Healthcare Publishing, 2008.
5. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 1896;ii:104–107.
6. Lipworth L. Epidemiology of breast cancer. Eur J Cancer Prevent 1995;4:7–30.
7. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2:133–140.
8. Lonning PE, editor. Endocrinology and treatment of breast cancer. Clin Endocrinol Metab 2004;18:1–130.
9. Quinn MJ, Cooper N, Rachet B, Mitry E, Coleman MP. Survival from cancer of the breast in women in England and Wales up to 2001. Br J Cancer 2008;99:S53–5.
10. Bradburn MJ, Altman DG, Smith P, Fentiman IS, Rubens RD. Time trends in breast cancer survival: experience in a single centre, 1975–89. Br J Cancer 1998;77:1944–1949.
11. Brown SB, Mallon EA, Edwards J, Campbell FM, McGlynn LM, Elsberger B, Cooke TG. Is the biology of breast cancer changing ? A study of hormone receptor status 1984–1986 and 1996–1997. Br J Cancer 2009;100:807–810.
12. Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 1994;74:1601–1606.
13. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003;21:28–34.
14. Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence 1980–2006: combined roles of menopausal hormone therapy, screening, mammography and estrogen receptor status. J Natl Cancer Inst 2007;99:1152–1161.
15. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713–1727.
16. Cuzick J. Hormone replacement therapy and the risk of breast cancer. Eur J Cancer 2008;44:2344–2349.
17. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian W.H. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95 (suppl 1):s1–66.
18. Darbre P, Yates J, Curtis SA, King RJ. Effect of estradiol on human breast cancer cells in culture. Cancer Res 1983;43:349–354.
19. Engel LW, Young NA. Human breast carcinoma cells in continuous culture: a review. Cancer Res 1978;38:4327–4339.
20. Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in longterm tissue culture. Cancer Res 1976;36:4595–4601.
21. Engel LW, Young NA, Tralka TS, Lippman ME, O' Brien SJ, Joyce MJ. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 1978;38:3352–3364.
22. Soule HD, Vazquez A, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409–1413.
23. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987;47:4355–4360.
24. Welshons WV, Jordan VC. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 1987;23:1935–1939.
25. Glover JF, Irwin JT, Darbre PD. Interaction of phenol red with estrogenic and antiestrogenic action on growth of human breast cancer cells ZR-75–1 and T-47-D. Cancer Res 1988;48: 3693–3697.
26. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 1986;83:2496–2500.
27. Darbre PD, Daly RJ, Effects of oestrogen on human breast cancer cells in culture. Proc R Soc Edinb 1989;95B:119–132.
28. Osborne CK, Hobbs K, Trent JM. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat 1987;9:111–121.
29. Toft D, Gorski J. A receptor molecule for estrogens: isolation from the ratuterus and preliminary characterization. Proc Natl Acad Sci USA 1966;55:1574–1581.
30. Jensen EV, DeSombre ER. Estrogen-receptor interaction. Science 1973;182:126–134.
31. Walter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, Scaub A, Jensen E, Scrace G, Waterfield M, Chambon P. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 1985;82:7889–7893.
32. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49–53.
33. Gustafsson JA. Estrogen receptor β. a new dimension in estrogen mechanism of action. J Endocrinol 1999;163:379–383.
34. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggbled J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863–870.
35. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753–758.
36. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engström O, Ljunggren J, Gustafsson JA, Carlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999;18:4608–4618.
37. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell 1987;51:941–951.
38. Oettel M, Schillinger E, editors. Estrogens and antiestrogens I. Berlin: Springer Verlag, 1999:1–397.
39. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA. Mechanisms of estrogen action. Physiol Rev 2001;81:1535–1565.
40. Cheskis BJ, Greger JG, Nagpal S, Freedman LP. Signaling by estrogens. J Cell Physiol 2007;213:610–617.
41. Acconcia F, Marino M. The effects of 17 β-estradiol in cancer are mediated by estrogen receptor signaling at the plasma membrane. Front Physiol 2011;2:1–8.
42. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003;115:715–763.
43. Reid G, Hubner MR, Metevier R, Brand H, Denger S, Manu D, Beaudoun J, Ellenberg J, Gannon F. Cyclic, proteasome-mediatedturnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003;11:695–707.
44. Picard N, Charbonneau C, Sanchez M, Licznar A, Busson M, Lazennec G, Tremblay A. Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor beta. Mol Endocrinol 2008;22:317–330.
45. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ. The estrogen receptor enhances AP1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999;13:1672–1685.
46. Safe S. Transcriptional activation of genes by 17beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001;62:231–252.
47. Pearce ST, Jordan VC. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 2004;50:3–22.
48. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor α and β: impact on human health. Mol Aspect Med 2006;27:299–402.
49. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982;10:7895–7903.
50. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990;9:1603–1614.
51. Krishnan V, Wang X, Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 1994;269:15912–15917.
52. Phimister B, editor. The chipping forecast. Nat Genet 1999;21:1–60.
53. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 2000;60:5977–5983.
54. Soulez M, Parker MG. Identification of novel oestrogen receptor target genes in human ZR75–1 breast cancer cells by expression profiling. J Mol Endocrinol 2001;27:259–274.
55. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 2002;29:175–192.
56. Kroll T, Odyvanova L, Clement JH, Platzer C, Naumann A, Marr N, Hoffken K, Wolfl S. Molecular characterization of breast cancer cell lines by expression profiling. J Cancer Res Clin Oncol 2002;128:125–134.
57. Lobenhofer EK, Bennett L, Cable PL, Li L, Bushel PR, Afshari CA. Regulation of DNA replication fork genes by 17 β-oestradiol. Mol Endocrinol 2002;16:1215–1229.
58. Cunliffe HE, Ringner M, Bilke S, Walker RL, Cheung JM, Chen Y, Meltzer PS. The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. Cancer Res 2003;63:7158–7166.
59. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profi ling of estrogen up-and downregulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinol 2003;144:4562–4574.
60. Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, Yosida N, Yamaguchi Y. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr Relat Cancer 2003;10:193–202.
61. Cicatiello L, Scaoglio C, Altucci L, Cancemi M, Natoli G, Facchiano A, Iazzetti G, Calgero R, Biglia N, Bortoli MD, Sfi ligio C, Sismondi P, Bresciani F, Weisz A. A genomic view estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol 2004;32:719–775.
62. Tee MK, Rogatsky I, Foster CT, Cvoro A, An J, Christy RJ, Yamamoto KR, Leitman DC. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol Biol Cell 2004;15:1262–1272.
63. Wang DY, Fulthorpe R, Liss SN, Edwards EA. Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol 2004;18:402–411.
64. DeNardo DG, Kim HT, Hilsenbeck S, Ciba V, Tsimelzon A, Brown PH. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol 2005;19:362–378.
65. Gadal F, Starzec A, Bozic C, Brochet CP, Malinge S, Ozanne V, Vicenzi J, Buffat L, Perret G, Iris F, Crepin M. Integrative analysis of gene expression patterns predicts specific modulations of defined cell functions by estrogen and tamoxifen in MCF7 breast cancer cells. J Mol Endocrinol 2005;34:61–75.
66. Santen RJ, Lobenhofer EK, Afshari CA, Bao Y, Song RX. Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat 2005;94:213–223.
67. Pugazhendhi D, Sadler AJ, Darbre PD. Comparison of the global gene expression profiles produced by methylparaben, n-butylparaben and 17 β-oestradiol in MCF7 human breast cancer cells. J Appl Toxicol 2007;27:67–77.
68. Sadler AJ, Pugazhendhi D, Darbre PD. Use of global gene expression patterns in mechanistic studies of oestrogen action in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 2009;114:21–32.
69. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Ann Rev Physiol 2005;67:285–308.
70. Miyoshi Y, Murase K, Saito M, Imamura M, Oh K. Mechanisms of estrogen receptor-β upregulation in breast cancers. Med Mol Morphol 2010;43:193–196.
71. Fox EM, Davis RJ, Shupnik MA. ER β in breast cancer. onlooker, passive player, or active protector ? Steroids 2008;73: 1039–1051.
72. Hartman J, Strom A, Gustafsson JA. Estrogen receptor beta in breast cancer. diagnostic and therapeutic implications. Steroids 2009;74:635–641.
73. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G 2 cell cycle arrest. Cancer Res 2004;64:423–428.
74. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor β inhibits 17 β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004;101:1566–1571.
75. Pugazhendhi D, Darbre PD. Differential effects of overexpression of ER α and ER β in MCF10A immortalized, non-transformed human breast epithelial cells. Horm Mol Biol Clin Invest 2010;1:117–126.
76. Jiang SY, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992;84:580–591.
77. Pilat MJ, Christman JK, Brooks SC. Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6. Breast Cancer Res Treat 1996;37:253–266.
78. Shaw LE, Sadler AJ, Pugazhendhi D, Darbre PD. Changes in oestrogen receptor-α and-β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 2006;99:19–32.
79. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1996;80:2918–2925.
80. Lewis JS, Osipo C, Meeke K, Jordan VC. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 2005;94: 131–141.
81. Lazennec G, Katzenellenbogen BS. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells. Mol Cell Endocrinol 1999;149:93–105.
82. Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, Ung K, Vendetti M, Shiu R. Inducible upregulation of oestrogen receptor-β1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 2005;34:553–566.
83. Tonetti DA, Rubenstein R, Deleon M, Zhao H, Pappas SG, Bentrem DJ, Chen B, Constantinou A, Jordan VC. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol 2003;87:47–55.
84. Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J, Shao ZM. ER β exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 2004;23:5799–5806.
85. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869–898.
86. Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 2010;16:2702–2708.
87. Pelekanou V, Kampa M, Gallo D, Notas G, Troullinaki M, Duvillier H, Jacquot Y, Sathopoulos EN, Castanas E, Ledercq G. The estrogen receptor alpha-derived peptide ER α 17p[P(295)-T(311)]exerts proapoptotic actions in breast cancer cells in vitro and in vivo, independently from their ER α status. Mol Oncol 2011;5:36–47.
88. Lippman ME. 8th San Antonio Breast Cancer Symposium. Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 1988;7: 59–70.
89. Wood TL, Yee D. IGFs and IGFBPs in the normal mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2000;5:1–115.
90. Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:423–429.
91. Lanzino M, Morelli C, Garofalo C, Panno ML, Mauro L, Ando S, Sisci D. Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr Cancer Drug Targets 2008;8:597–610.
92. Daly RJ, Harris WH, Wang DY, Darbre PD. Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Differ 1991;2:457–464.
93. Cullen KJ, Lippman ME, Chow D, Hill S, Rosen N, Zwiebel JA. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol 1992;6:91–100.
94. Arteaga CL, Coronado E, Osborne CK. Blockade of the epidermal growth factor receptor inhibits transforming growth factor α-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol 1988;2:1064–1069.
95. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989;49:6237–6241.
96. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435–2446.
97. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAPkinase pathway and direct phosphorylation. EMBO J 1996;15:2174–2183.
98. Lee A, Weng C, Jackson J, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-1 in human breast cancer cells. J Endocrinol 1997;152:786–794.
99. Abdul-Wahab K, Corcoran D, Perachiotti A, Darbre PD. Overexpression of insulin-like growth factor II (IGF II) in ZR-75–1 human breast cancer cells: higher threshold levels of receptor (IGF1R) are required for a proliferative response than for effects of specific gene expression. Cell Prolif 1999;32:271–287.
100. Selye H. Correlations between the chemical structure and the pharmacological actions of the steroids. Endocrinol 1942;30:437–453.
101. Acconia F, Totta P, Ogawa S, Cardillo I, Inoue S, Leone S, Trentalance A, Muramatsu M, Marino M. Survival versus apoptotic 17 β-estradiol effect: role of ER α and ER β activated nongenomic signaling. J Cell Physiol 2005;203:193–201.
102. Marino M, Ascenzi P. Membrane association of estrogen receptor α and β influences 17 β-oestradiol-mediated cancer cell proliferation. Steroids 2008;73:853–858.
103. Caldon CE, Sutherland RL Musgrove EA. Cell cycle proteins in epithelial cell differentiation. Cell Cycle 2010;9:1918–1928.
104. Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987;47:6517–6521.
105. Dubik D, Shiu RP. Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 1988;263:12705–12708.
106. Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992;7:1587–1594.
107. Butt AJ. McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signaling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005;12:S47–59.
108. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, DeFazio A, Watts CK, Musgrove EA, Sutherland RL. Expression and amplifi cation of cyclin genes in human breast cancer. Oncogene 1993;8:2127–2133.
109. Barbareschi M, Pelosio P, Caffo O, Buttitta F, Pellegrini S, Barbazza R, Dalla Palma P, Bevilacqua G, Marchetti A. Cycin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retino-blastoma gene product, p53 and p21 WAF1 immunohistochemical expression. Int J Cancer 1997;74:171–174.
110. Utsumi T, Yoshimura N, Maruta M, Takeuchi S, Ando J, Mizoguchi Y, Harada N. Correlation of cyclin D1 mRNA levels with clinico-pathological parameters and clinical outcome in human breast carcinomas. Int J Cancer 2000;89:39–43.
111. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK, Sutherland RL. Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993;13:3577–3587.
112. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, truss M, Beato M, Sica V, Bresciani F, Weisz A. 17beta-Oestradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during miotogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996;12:2315–2324.
113. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL. Estrogen-induced activation of cdk4 and cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclinE-cdk2. J Biol Chem 1997;272:10882–10894.
114. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signaling cascades from diverse classes of receptors at the cyclinDcyclin-dependent-kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 1996;16:6917–6925.
115. Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B. Estrogen and insulin/IGF1 cooperativity stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 2005;229:161–173.
116. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
117. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit ? Breast Cancer Res 2009;11:206–218.
118. Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M, Rostene W. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000;65:593–598.
119. Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde MP, Vyhlidal C, Safe S. Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 1999;274:32099–32107.
120. Mor G, Kohen F, Garcia-Velasco J,Nilsen J, Brown W, Song J, Naftolin F. Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000:73:185–194.
121. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang JP, Santer R.J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 β-estradiol. J Natl Cancer Inst 2001;93:1714–1723.
122. Song RX, Santen RJ. Apoptotic action of estrogen. Apoptosis 2003;8:55–60.
123. Ingle JN, Ahmann DL, Green SJ, Edmondson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S. Randomised clinical trial of diethylstilboestrol versus tamoxifen in postmenopausal women with advanced breast cancer. New Engl J Med 1981;304:16–21.
124. DePasquale JA. Rearrangement of the F-actin cytoskeleton in estradiol-treated MCF-7 breast carcinoma cells. Histochem Cell Biol 1999;112:341–350.
125. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ. Linkage of rapid estrogen action to MAPK activation by ER α-Shc association and Shc pathway activation. Mol Endocrinol 2002;16:116–127.
126. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003;116:8–16.
127. Li Y, Wang JP, Santen RJ, Kim TH, Park H, Fan P, Yue W. Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology 2010;151:5146–5156.
128. Sanchez AM, Flamini MI, Baldacci C, Goglia L, Genazzi AR, Simoncini T. Estrogen receptor-a promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 2010;24:2114–2125.
129. Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Gennazzani AR, Simoncini T. Extra-nuclear signaling of estrogen receptor to breast cancer cytoskeletal remodeling, migration and invasion. PLoS One 2008;3:e2238.
130. Baranwal S, Alahari SK. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochim Biophys Res Commun 2009;384:6–11.
131. daSilva BB, dosSantos AR, Pires CG, Correa-Lima MA, Pereira-Filho JD, dos Santos LG, Moura CS, Lopes-Costa PV. E-cadherin expression in estrogen receptor-positive and negative breast carcinomas of postmenopausal women. Eur J Gynaecol Oncol 2010;31:90–93.
132. Sapino A, Pietribiasi F, Bussolati G, marchisio PC. Estrogenand tamoxifen-induced rearrangement of cytoskeletal and adhesion structures in breast cancer MCF-7 cells. Cancer Res 1986;46:2526–2531.
133. Planas-Silva MD, Waltz PK. Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 2007;104:11–21.
134. Ye Y, Xiao Y, Wnag W, Yearsley K, Gao JX, Shetuni B, Barsky SH. ER α signaling through slug regulates E-cadherin and EMT. Oncogene 2010;29:1451–1462.
135. Hugo HJ, Kokkinos MI, Blick T, Ackland ML, Thompson EW, Newgreen DF. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study. Cells Tissues Organs 2011;193:23–40.
136. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-Cadherin in breast cancer. Cancer Res 2002;62:1613–1618.
137. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 2009;9:188–208.
138. Van den Brule FA, Engel J, Stetler-Stevenson WG, Liu FT, Sobel ME, Castronovo V. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast cancer cells. Int J Cancer 1992;52:653–657.
139. Kousidou OC, Berdiaki A, Kletsas D, Zafiropoulos A, Theocharis AD, Tzanakakis GN, Karamanos NK. Estradiol-oestrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2008;2:223–232.
140. Song RX, Zhang Z, Chen Y, Bao Y, Santen RJ. Estrogen signaling via a linear pathway involving insulin-like growth factor 1 receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 2007;148: 4091–4101.
141. Qin W, Zhu W, Hewett JE, Rottinghaus G, Chen YC, Flynn JT, Kliethermes B, Mannello F, Sauter ER. uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer. BMC Cancer 2008;8:298.
142. Levenson AS, Kwaan HC, Svoboda KM, Weiss IM, Sakurai S, Jordan VC. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably overexpressing the oestrogen receptor. Br J Cancer 1998;78:88–95.
143. Clemons M, Danson S, Howell A. Tamoxifen (‘Nolvadex’): a review. Cancer Treat Rev 2002;28:165–180.
144. Howell SJ, Johnston SR, Howell A. The use of selective estrogen receptor modulators and selective estrogen downregulators in breast cancer. Clin Endocrinol Metab 2004; 18:47–66.
145. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643–658.
146. Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res 2001;7(supp12):4369s-75s.
147. Bundred N, Howell A. Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev Anticancer Ther 2002;2:151–160.
148. Lonning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol 2011;22:503–514.
149. Pike AC. Lessons learnt from structural studies of the oestrogen receptor. Best Pract Res Clin Endocrinol Metab 2006;20:1–14.
150. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheeng AS, Li L, Abbosh PH, Huang TH, Nephew KP. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antioestrogens tamoxifen and fulvestrant. Cancer Res 2006;66:11954–11966.
151. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI182,780 (Faslodex). Endocrinology 2001;142:2776–2788.
152. Jensen BL, Skouv J, Lundholt BK, Lykkesfeldt AE. Differential regulation of specific genes in MCF-7 and ICI182780-resistant cell line MCF-7/182R-6. Br J Cancer 1999;79:386–392.
153. Fan M, Bigsby RM, Nephew KP. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor(ER)-α and essential for the antiproliferative activity of ICI 182,780 in ER α-positive breast cancer cells. Mol Endocrinol 2003;17:356–365.
154. Mullick A, Chambon P. Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. Cancer Res 1990;50:333–338.
155. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144:1032–1044.
156. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI182,780. Cancer Res 1993;53:3229–3232.
157. Badia E, Duchesne MJ, Semlali A, Fuentes M, Giamarchi C, Richard-Foy H, Nicholas JC, Pons M. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res 2000;60:4130–4138.
158. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988;48: 5183–5187.
159. Daly RJ, Darbre PD. Cellular and molecular events in losso of estrogen sensitivity in ZR-75–1 and T-47-D human breast cancer cells. Cancer Res 1990;50:5868–5875.
160. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S, Santen RJ. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998;139:4164–4174.
161. Stephen R, Darbre PD. Loss of growth inhibitory effects of retinoic acid in human breast cancer cells following long-term exposure to retinoic acid. Br J Cancer 2000;83: 1183–1191.
162. Stephen RL, Shaw LE, Larsen C, Corcoran D, Darbre PD. Insulin-like growth factor receptor levels are regulated by cell density and by long-term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 2001;276:40080–40086.
163. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on longterm oestrogen deprivation. J Steroid Biochem Mol Biol 2002;81:333–341.
164. Yue W, Wang JP, Conaway MR, Li Y, Santen RJ. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol 2003;86:265–274.
165. Murphy CS, Meisner LF, Wu SQ, Jordan VC. Short-and longterm estrogen deprivation of T47D human breast cancer cells in culture. Eur J Cancer Clin Oncol 1989;25:1777–1788.
166. Saceda M, Lippman ME, Chambon P, Lindsey RL, Ponglikitmongkol M, Puente M, Martin MB. Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol 1988;2:1157–1162.
167. Staka CM, Nicholson RI, Gee JM. Acquired resistance to oestrogen deprivation: role for growth factor signaling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr Relat Cancer 2005;12:S85–97.
168. Shaw LE, Sadler AJ, Pugazhendhi D, Darbre PD. Changes in oestrogen receptor-α and-β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 2006;99:19–32.
169. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Lawrence Jr J, MacMahon LP, Yue W, Berstein L. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005;95:155–165.
170. Daly RJ, Darbre PD. Interaction of growth factors during progression towards steroid independence in T-47-D human breast cancer cells. J Cell Biochem 1990;43:199–211.
171. Herman ME, Katzenellenbogen BS. Alterations in transforming growth factor-α and-β production and cell responsiveness during progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 1994;54: 5867–5874.
172. Shim WS, Conaway M, Masamura S. Estradiol hypersensitivity and mitogen-activated protein kinase expression in longterm estrogen deprived human breast cancer cells in vivo. Endocrinology 2000;141:396–405.
173. Santen R, Jeng MH, Wang JP. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001;79:115–125.
174. Yue W, Wang JP, Conaway M, Masamura S, Li Y, Santen RJ. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 2002;143:3221–3229.
175. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278:30458–30468.
176. Sabnis GJ, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005;65: 3903–3910.
177. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK. S6 kinase 1 regulates estrogen receptor α in control of breast cancer cell proliferation. J Biol Chem 2009;284: 6361–6369.
178. Yue W, Wang J, Li Y, Fan P, Santen RJ. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int J Cancer 2005;117:746–754.
179. Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med 2008;630:19–34.
180. Ray S, Fry MJ, Darbre PD. Enhanced sensitivity to rapamycin following long-term oestrogen deprivation in MCF-7, T-47-D and ZR-75–1 human breast cancer cells. J Endocrinol 2011;208:21–29.
181. Ray S, Darbre PD. Crosstalk with insulin and dependence on PI3K/Akt/mTOR rather than MAPK pathways in upregulation of basal growth following long-term oestrogen deprivation in three human breast cancer cell lines. Horm Mol Biol Clin Invest 2011;5:53–65.
182. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596–603.
183. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68:3077–3080.
184. Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 1995;61:529–534.
185. Sommer A, Hoffman J, Lichtner RB, Schneider MR, Parczyk K. Studies on the development of resistance to the pure antiestrogen Faslodex TM in three human breast cancer cell lines. J Steroid Biochem Mol Biol 2003;85:33–47.
186. Larsen SS, Madsen MW, Jensen BL, Lykkesfeldt AE. Resistance of human breast cancer cells to the pure steroidal anti-estrogen ICI182,780 is not associated with a general loss of estrogenreceptor expression or lack of estrogen responsiveness. Int J Cancer 1997;72:1129–1136.
187. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992;89: 4037–4041.
188. Giamarchi C, Chailleux C, Callige M, Rochaix P, Trouche D, Richard-Foy H. Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells. Biochim Biophys Acta 2002;1578:12–20.
189. Gee JM, Nicholson RI, Barrow D, Dutkowski CM, Goddard L, Jordan NJ, McClelland RA, Knowlden JM, Francies HE, Hiscox SE, Hutcheson IR. Antihormone induced compensatory signaling in breast cancer: an adverse event in the development of endocrine resistance. Horm Mol Biol Clin Invest 2011;5:67–77.
190. Summy JM, Gallick GE. Src family kinases in tumour progression and metastasis. Cancer Metastasis Rev 2003;22:337–358.
191. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470–480.
192. Frame MC. Src in cancer: deregulation and consequences for cell behavior. Biochim Biophys Acta 2002;1602:114–130.
193. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley-Smith J. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 2006;341:73–81.
194. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in Tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97:263–274.
195. Planas-Silva MD, Hamilton KN. Targeting of c-Src kinase enhances tamoxifen ' s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Cancer Chemother Pharmacol 2007;60:535–543.
196. Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 2009;115:57–67.
197. Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Hisaaki K, Nicholson R, Hiscox S. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 2009;8:1550–1558.
198. Burstein HJ, Prestud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs J.J. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28: 3784–3796.
199. Zhou D, Pompon D, Chen S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990;50:6949–6954.
200. Sun XZ, Zhou D, Chen S. Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J Steroid Biochem Mol Biol 1997;63:29–36.
201. Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O. Model systems: mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol 2005; 95:41–48.
202. Brodie A, Macedo L, Sabnis G. Aromatase resistance mechanisms in model systems in vivo. J Steroid Biochem Mol Biol 2010;118:283–287.
203. Sabnis G, Brodie A. Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Mol Cell Endocrinol 2011;340:142–147.
204. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 2011;125:13–22.
205. Brodie AM, Chumsri S, Sukumar S, Sabnis GJ. Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. Horm Mol Biol Clin Invest 2011;5:97–103.
206. Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Mol Cancer Res 2005;3:203–218.
207. Darbre PD. Environmental oestrogens, cosmetics and breast cancer. Best Pract Res Clin Endocrinol Metab 2006;20: 121–143.
208. Darbre PD, Charles AK. Environmental oestrogens and breast cancer: evidence for combined involvement of dietary, household and cosmetic xenoestrogens. Anticancer Res 2010;30: 815–828.
209. Blair RM, Fang H, Branham WS, Hass BS, Dial SL, Moland CL, Tong W, Shi L, Perkins R, Sheehan DM. The estrogen receptor relative binding affi nities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci 2000;54: 138–153.
210. Darbre PD, editor. Endocrine disrupters. Best Pract Res Clin Endocrinol Metab 2006;20:1–165.
211. Darbre PD, Harvey PW. Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. J Appl Toxicol 2008;28:561–578.
212. Damstra T, Barlow S, Bergman A, Kavlock R, Kraak GV, editors. Global Assessment of the State-of-the-Science of Endocrine Disruptors. Geneva: World Health Organisation, pp. 1–180, 2002 [available online www.who.int./ipcs/publications/endocrine_disrupters/endocrine_disruptors/en/]. Accessed 3 January 2012.
213. Snedeker SM. Pesticides and breast cancer risk: a review of DDT, DDE, and dieldrin. Environ Health Perspect 2001;109: 35–47.
214. Brody JG, Rudel RA. Environmental pollutants and breast cancer. Environ Health Perspect 2003;111:1007–1019.
215. Furst P. Dioxins. Polychlorinated biphenyls and other organohalogen compounds in human milk. Mol Nutr Food Res 2006;50:922–933.
216. Woods HF (Chairman). Phytoestrogens and health. London: Food Standards Agency Publication. Crown Copyright, 2003 [available online http://cot.food.gov.uk/pdfs/phytoreport0503]. Accessed on January 3, 2012.
217. Kuruto-Niwa R, Tateoka Y, Usuki Y, Nozawa R. Measurement of bisphenol A concentrations in human colostrum. Chemosphere 2007;66:1160–1164.
218. Calafat AM, Slakman AR, Silva MJ, Herbert AR, Needham LL. Automated solid-phase extraction and quantitative analysis of human milk for 13 phthalate metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 2004;805:49–56.
219. Hines EP, Calafat AM, Silva MJ, Mendola P, Fenton SE. Concentrations of phthalate metabolites in milk, urine, saliva, and serum of lactating North Carolina women. Environ Health Perspect 2009;117:86–92.
220. Ademollo N, Ferrera F, Delise M, Fabietti F, Funari E. Nonylphenol and octylphenol in human breast milk. Environ Int 2008;34:984–987.
221. Schecter A, Pavuk M, Papke O, Ryan JJ, Birnbaum L, Rosen R. Polybrominated dipheylethers (PBDEs) in US mother's milk. Environ Health Perspect 2003;111:1723–1729.
222. Kalantzi OI, Martin FL, Thomas GO, Alcock RE, Tang HR, Drury SC, Carmichael PL, Nicholson JK, Jones KC. Different levels of polybrominated diphenyl ethers (PBDEs) and chlorinated compounds in breast milk from two UK regions. Environ Health Perspect 2004;112:1085–1091.
223. Costa LG, Giordano G, Tagliaferri S, Caglieri A, Mutti A. Polybrominated diphenyl ethers (PBDE) flame retardants: environmental contamination, human body burden development of endocrine resistance. Horm Mol Biol Clin Invest 2011;5:67–77.
224. Summy JM, Gallick GE. Src family kinases in tumour progression and metastasis. Cancer Metastasis Rev 2003;22:337–358.
225. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470–480.
226. Frame MC. Src in cancer: deregulation and consequences for cell behavior. Biochim Biophys Acta 2002;1602:114–130.
227. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley-Smith J. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 2006;341:73–81.
228. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in Tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97:263–274.
229. Planas-Silva MD, Hamilton KN. Targeting of c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Cancer Chemother Pharmacol 2007;60:535–543.
230. Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 2009;115:57–67.
231. Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Hisaaki K, Nicholson R, Hiscox S. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 2009;8:1550–1558.
232. Burstein HJ, Prestud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs J.J. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28: 3784–3796.
233. Zhou D, Pompon D, Chen S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990;50:6949–6954.
234. Sun XZ, Zhou D, Chen S. Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J Steroid Biochem Mol Biol 1997;63:29–36.
235. Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O. Model systems: mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol 2005; 95:41–48.
236. Brodie A, Macedo L, Sabnis G. Aromatase resistance mechanisms in model systems in vivo. J Steroid Biochem Mol Biol 2010;118:283–287.
237. Sabnis G, Brodie A. Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Mol Cell Endocrinol 2011;340:142–147.
238. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 2011;125:13–22.
239. Brodie AM, Chumsri S, Sukumar S, Sabnis GJ. Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. Horm Mol Biol Clin Invest 2011;5:97–103.
240. Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S. Letrozole-, anastrozole-, and tamoxifen-responsive genes and potential adverse health effects. Acta Biomed 2008;79: 172–183.
241. Darbre PD. Underarm cosmetics are a cause of breast cancer. Eur J Cancer Prev 2001;10:389–393.
242. Darbre PD: Underarm cosmetics and breast cancer. J Appl Toxicol 2003;23:89–95.
243. Donovan M, Tiwary CM, Axelrod D, Sasco AJ, Jones L, Hajek R, Sauber E, Kuo J, Davis D.L. Personal care products that contain estrogens or xenoestrogens may increase breast cancer risk. Med Hypotheses 2007;68:756–766.
244. Darbre PD. Underarm antiperspirants/deodorants and breast cancer. Breast Cancer Res 2009;11(suppl 3):S5.
245. Dobson S, editor. DDT and its derivatives. environmental aspects. Environmental Health Criteria 1989;83:1–79.
246. Dobson S, editor. Polychlorinated biphenyls and terphenyls. Environmental Health Criteria 1993;140:1–682.
247. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinol 1998;139:4252–4263.
248. Darbre PD. Metalloestrogens: an emerging class of inorganic xenoestrogens with potential to add to the oestrogenic burden of the human breast. J Appl Toxicol 2006;26:191–197.
249. McElroy JA, Shafer MM, Trentham-Dietz A, Hampton JM, Newcomb PA. Cadmium exposure and breast cancer risk. J Natl Cancer Inst 2006;98:869–873.
250. Darbre PD, Pugazhendhi D, Mannello F. Aluminium and human breast diseases. J Inorg Biochem 2011;105:1484–1488.
251. Filby AL, Neupath T, Thorpe KL, Owen R, Galloway TS, Tyler CR. Health impacts of estrogens in the environment, considering complex mixture effects. Environ Health Perspect 2007;115:1704–1710.
252. Kortenkamp A. Ten years of mixing cocktails: a review of combination effects of endocrine-disrupting chemicals. Environ Health Perspect 2007;115:98–105.
253. Russo J, Russo IH. Biology of disease. Biological and molecular bases of mammary carcinogenesis. Lab Invest 1987;57: 112–137.
254. McLachlan JA, Simpson E, Martin M. Endocrine disrupters and female reproductive health. Best Pract Res Clin Endocrinol Metab 2006;20:63–75.
255. Durando M, Kass L, Piva J, Sonnenschein C, Soto AM, Luque EH, Munoz-de-Toro M. Prenatal bisphenol A exposure induces preneoplastic lesions in the mammary gland in Wistar rats. Environ Health Perspect 2007;115:80–86.
256. Moggs JG, Ashby J, Tinwell H, Lim FL, Moore DJ, Kimber I, Orphanides G. The need to decide if all estrogens are intrinsically similar. Environ Health Perspect 2004;112:1137–1142.
257. Singleton DW, Feng Y, Yang J, Puga A, Lee AV, Khan S.A. Gene expression profiling reveals novel regulation by bisphenol-A in estrogen receptor-α-positive human cells. Environ Res 2006;100:86–92.
258. Terasaka S, Inoue A, Tanji M, Kiyama R. Expression profiling of estrogen-responsive genes in breast cancer cells treated with alkylphenols, chlorinated phenols, parabens, or bis-and benzoylphenols for evaluation of estrogenic activity. Toxicol Lett 2006;163:130–141.
259. Dip R, Lenz S, Antignac JP, LeBizec B, Gmiender H, Naegli H. Global gene expression profiles induced by phytoestrogens in human breast cancer cells. Endocr Relat Cancer 2008;15:161–173.
260. Strange PG. Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol 2008;153:1353–1363.
261. Rajapakse N, Silva E, Kortenkamp A. Combining xenoestrogens at levels below no-observed-effect concentrations dramatically enhances steroid hormone action. Environ Health Perspect 2002;110:917–921.
262. Gee RH, Charles A, Taylor N, Darbre PD. Oestrogenic and androgenic activity of triclosan in breast cancer cells. J Appl Toxicol 2008;28:78–91.
263. Charles AK, Darbre PD. Oestrogenic activity of benzyl salicylate, benzyl benzoate and butylphenylmethylpropional (Lilial) in MCF7 human breast cancer cells in vitro. J Appl Toxicol 2009;29:422–434.
264. Whitehead SA, Rice S. Endocrine-disrupting chemicals as modulators of sex steroid synthesis. Best Pract Res Clin Endocrinol Metab 2006;20:45–61.
265. Chang M. Dual roles of estrogen metabolism in mammary carcinogenesis. BMB Rep 2011;44:423–434.
266. International Agency for Research on Cancer (IACR) Monographs 1974;6:99.
267. International Agency for Research on Cancer (IACR) Monographs 1979;21:279.
268. International Agency for Research on Cancer (IACR) Monographs 1987; Suppl 7:284.
269. International Agency for Research on Cancer (IACR) Monographs 1999:72:399.
270. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006;102: 89–96.
271. Russo J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff S, Lareef HM, Garber J, Russo IH. 17-beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J 2006;20: 1622–1634.
272. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6075–6086.
273. Paine TM, Soule HD, Pauley RJ, Dawson PJ. Characterization of epithelial phenotypes in mortal and immortal human breast cells. Int J Cancer 1992;50:463–473.
274. Shin SI, Freedman VH, Risser R, Pollack R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifi cally with anchorage-independent growth in vitro. Proc Natl Acad Sci USA 1975;72:4435–9